{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:44:10Z","timestamp":1791924250439,"version":"4.3.4"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T00:00:00Z","timestamp":1588809600000},"content-version":"am","delay-in-days":341,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Unizyme"},{"DOI":"10.13039\/501100004792","name":"Minist\u00e8re de l'Enseignement Sup\u00e9rieur et de la Recherche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004792","id-type":"DOI","asserted-by":"publisher"}]},{"name":"R\u00e9gion Centre"},{"name":"National Science Center Poland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bcp.2019.04.006","type":"journal-article","created":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T12:54:30Z","timestamp":1554814470000},"page":"349-367","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C"],"prefix":"10.1016","volume":"164","author":[{"given":"Brice","family":"Korkmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lesner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Wysocka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Gieldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"H\u00e5kansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek T.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dieter E.","family":"Jenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conni","family":"Lauritzen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2019.04.006_b0005","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.4049\/jimmunol.150.11.4733","article-title":"Dipeptidyl peptidase I is enriched in granules of in vitro- and in vivo-activated cytotoxic T lymphocytes","volume":"150","author":"Brown","year":"1993","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.04.006_b0010","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.pharmthera.2018.05.011","article-title":"Therapeutic targeting of cathepsin C: from pathophysiology to treatment","volume":"190","author":"Korkmaz","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.bcp.2019.04.006_b0015","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/S0021-9258(18)53798-4","article-title":"Generation of active myeloid and lymphoid granule serine proteases requires processing by the granule thiol protease dipeptidyl peptidase I","volume":"268","author":"McGuire","year":"1993","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0020","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/S0003-9861(02)00217-5","article-title":"Dipeptidyl peptidase I: importance of progranzyme activation sequences, other dipeptide sequences, and the N-terminal amino group of synthetic substrates for enzyme activity","volume":"403","author":"Tran","year":"2002","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.bcp.2019.04.006_b0025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1172\/JCI0213462","article-title":"Dipeptidyl peptidase I activates neutrophil-derived serine proteases and regulates the development of acute experimental arthritis","volume":"109","author":"Adkison","year":"2002","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.04.006_b0030","doi-asserted-by":"crossref","first-page":"7277","DOI":"10.4049\/jimmunol.173.12.7277","article-title":"Papillon-Lefevre syndrome: correlating the molecular, cellular, and clinical consequences of cathepsin C\/dipeptidyl peptidase I deficiency in humans","volume":"173","author":"Pham","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.04.006_b0035","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.4049\/jimmunol.1301293","article-title":"NSP4 is stored in azurophil granules and released by activated neutrophils as active endoprotease with restricted specificity","volume":"191","author":"Perera","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.bcp.2019.04.006_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/imr.12440","article-title":"Granulopoiesis and granules of human neutrophils","volume":"273","author":"Cowland","year":"2016","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.bcp.2019.04.006_b0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5414\/CNP66153","article-title":"Production and applications of recombinant proteinase 3, Wegener\u2019s autoantigen: problems and perspectives","volume":"66","author":"Jenne","year":"2006","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.bcp.2019.04.006_b0050","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1124\/pr.110.002733","article-title":"Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases","volume":"62","author":"Korkmaz","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.bcp.2019.04.006_b0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.biochi.2007.10.009","article-title":"Neutrophil elastase, proteinase 3 and cathepsin G: physicochemical properties, activity and physiopathological functions","volume":"90","author":"Korkmaz","year":"2008","journal-title":"Biochimie"},{"key":"10.1016\/j.bcp.2019.04.006_b0060","first-page":"82","article-title":"2 cases of symmetrically, familiarly palmar and plantar hyperkeratosis (Meleda disease) within brother and sister combined with severe dental alterations in both cases","volume":"31","author":"Papillon","year":"1924","journal-title":"Soc. Franc. Dermat. Syph."},{"key":"10.1016\/j.bcp.2019.04.006_b0065","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/70525","article-title":"Loss-of-function mutations in the cathepsin C gene result in periodontal disease and palmoplantar keratosis","volume":"23","author":"Toomes","year":"1999","journal-title":"Nat. Genet."},{"key":"10.1016\/j.bcp.2019.04.006_b0070","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/jmg.36.12.881","article-title":"Mutations of the cathepsin C gene are responsible for Papillon-Lefevre syndrome","volume":"36","author":"Hart","year":"1999","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.bcp.2019.04.006_b0075","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0022-3476(64)80014-7","article-title":"The syndrome of palmar-plantar hyperkeratosis and premature periodontal destruction of the teeth. A clinical and genetic analysis of the Papillon-Lef'evre syndrome","volume":"65","author":"Gorlin","year":"1964","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcp.2019.04.006_b0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00278288","article-title":"Papillon-Lefevre syndrome: keratosis palmoplantaris with periodontopathy. Report of a case and review of the cases in the literature","volume":"51","author":"Haneke","year":"1979","journal-title":"Hum. Genet."},{"key":"10.1016\/j.bcp.2019.04.006_b0085","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2009.03.016","article-title":"Papillon-Lefevre syndrome: clinical presentation and a brief review","volume":"108","author":"Dhanrajani","year":"2009","journal-title":"Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod."},{"key":"10.1016\/j.bcp.2019.04.006_b0090","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.bcp.2017.02.009","article-title":"Prolonged pharmacological inhibition of cathepsin C results in elimination of neutrophil serine proteases","volume":"131","author":"Guarino","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2019.04.006_b0095","doi-asserted-by":"crossref","first-page":"4539","DOI":"10.1172\/JCI76009","article-title":"Papillon-Lefevre syndrome patient reveals species-dependent requirements for neutrophil defenses","volume":"124","author":"Sorensen","year":"2014","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bcp.2019.04.006_b0100","doi-asserted-by":"crossref","first-page":"12415","DOI":"10.1074\/jbc.RA118.001922","article-title":"Consequences of cathepsin C inactivation for membrane exposure of proteinase 3, the target antigen in autoimmune vasculitis","volume":"293","author":"Seren","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s00281-013-0362-z","article-title":"Neutrophil proteinase 3 and dipeptidyl peptidase I (cathepsin C) as pharmacological targets in granulomatosis with polyangiitis (Wegener granulomatosis)","volume":"35","author":"Korkmaz","year":"2013","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.bcp.2019.04.006_b0110","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1002\/art.21192","article-title":"Dipeptidyl peptidase I regulates the development of collagen-induced arthritis","volume":"52","author":"Hu","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.bcp.2019.04.006_b0115","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1021\/bi001693z","article-title":"Human recombinant pro-dipeptidyl peptidase I (cathepsin C) can be activated by cathepsins L and S but not by autocatalytic processing","volume":"40","author":"Dahl","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.bcp.2019.04.006_b0120","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1006\/prep.1998.0976","article-title":"Active recombinant rat dipeptidyl aminopeptidase I (cathepsin C) produced using the baculovirus expression system","volume":"14","author":"Lauritzen","year":"1998","journal-title":"Protein Expr. Purif."},{"key":"10.1016\/j.bcp.2019.04.006_b0125","doi-asserted-by":"crossref","first-page":"6570","DOI":"10.1093\/emboj\/20.23.6570","article-title":"Structure of human dipeptidyl peptidase I (cathepsin C): exclusion domain added to an endopeptidase framework creates the machine for activation of granular serine proteases","volume":"20","author":"Turk","year":"2001","journal-title":"EMBO J."},{"key":"10.1016\/j.bcp.2019.04.006_b0130","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.bbapap.2011.10.002","article-title":"Cysteine cathepsins: from structure, function and regulation to new frontiers","volume":"1824","author":"Turk","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.bcp.2019.04.006_b0135","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1042\/BJ20061389","article-title":"The crystal structure of human dipeptidyl peptidase I (cathepsin C) in complex with the inhibitor Gly-Phe-CHN2","volume":"401","author":"Molgaard","year":"2007","journal-title":"Biochem. J."},{"key":"10.1016\/j.bcp.2019.04.006_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bcp.2019.04.006_b0145","doi-asserted-by":"crossref","first-page":"21626","DOI":"10.1074\/jbc.270.37.21626","article-title":"Oligomeric structure and substrate induced inhibition of human cathepsin C","volume":"270","author":"Dolenc","year":"1995","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0150","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1046\/j.1432-1327.1999.00697.x","article-title":"Location of the binding site for chloride ion activation of cathepsin C","volume":"264","author":"Cigic","year":"1999","journal-title":"Eur. J. Biochem."},{"key":"10.1016\/j.bcp.2019.04.006_b0155","doi-asserted-by":"crossref","first-page":"3614","DOI":"10.1016\/j.bmcl.2006.01.102","article-title":"Dipeptidyl nitriles as human dipeptidyl peptidase I inhibitors","volume":"16","author":"Bondebjerg","year":"2006","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.04.006_b0160","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1021\/jm401705g","article-title":"Cathepsin C inhibitors: property optimization and identification of a clinical candidate","volume":"57","author":"Furber","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0165","doi-asserted-by":"crossref","first-page":"5392","DOI":"10.1016\/j.bmcl.2009.07.114","article-title":"Design and synthesis of dipeptidyl nitriles as potent, selective, and reversible inhibitors of cathepsin C","volume":"19","author":"Guay","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.04.006_b0170","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1517\/13543771003657172","article-title":"Inhibitors of cathepsin C (dipeptidyl peptidase I)","volume":"20","author":"Laine","year":"2010","journal-title":"Expert. Opin. Ther. Pat."},{"key":"10.1016\/j.bcp.2019.04.006_b0175","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1021\/ml100212k","article-title":"Discovery of novel cyanamide-based inhibitors of cathepsin C","volume":"2","author":"Laine","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.bcp.2019.04.006_b0180","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1111\/bcp.13398","article-title":"Epithelial desquamation observed in a phase I study of an oral cathepsin C inhibitor (GSK2793660)","volume":"83","author":"Miller","year":"2017","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.bcp.2019.04.006_b0185","doi-asserted-by":"crossref","first-page":"9457","DOI":"10.1021\/acs.jmedchem.6b01127","article-title":"Discovery of second generation reversible covalent DPP1 inhibitors leading to an oxazepane amidoacetonitrile based clinical candidate (AZD7986)","volume":"59","author":"Doyle","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0190","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1124\/mol.108.045682","article-title":"In vivo inhibition of serine protease processing requires a high fractional inhibition of cathepsin C","volume":"73","author":"Methot","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.bcp.2019.04.006_b0195","doi-asserted-by":"crossref","first-page":"20836","DOI":"10.1074\/jbc.M702615200","article-title":"Inhibition of the activation of multiple serine proteases with a cathepsin C inhibitor requires sustained exposure to prevent pro-enzyme processing","volume":"282","author":"Methot","year":"2007","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0200","doi-asserted-by":"crossref","first-page":"708","DOI":"10.2174\/156802610791113469","article-title":"Therapeutic utility and medicinal chemistry of cathepsin C inhibitors","volume":"10","author":"Guay","year":"2010","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.bcp.2019.04.006_b0205","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1107\/S090744491200251X","article-title":"JLigand: a graphical tool for the CCP4 template-restraint library","volume":"68","author":"Lebedev","year":"2012","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bcp.2019.04.006_b0210","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1107\/S0907444910045749","article-title":"Overview of the CCP4 suite and current developments","volume":"67","author":"Winn","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bcp.2019.04.006_b0215","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1107\/S0907444911001314","article-title":"REFMAC5 for the refinement of macromolecular crystal structures","volume":"67","author":"Murshudov","year":"2011","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bcp.2019.04.006_b0220","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1107\/S0907444910007493","article-title":"Features and development of Coot","volume":"66","author":"Emsley","year":"2010","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bcp.2019.04.006_b0225","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1107\/S0907444900014736","article-title":"Use of TLS parameters to model anisotropic displacements in macromolecular refinement","volume":"57","author":"Winn","year":"2001","journal-title":"Acta Crystallogr. D Biol. Crystallogr."},{"key":"10.1016\/j.bcp.2019.04.006_b0230","doi-asserted-by":"crossref","first-page":"294","DOI":"10.2174\/156802610790725452","article-title":"Development of nitrile-based peptidic inhibitors of cysteine cathepsins","volume":"10","author":"Frizler","year":"2010","journal-title":"Curr. Top. Med. Chem."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301418?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295219301418?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:08:49Z","timestamp":1757768929000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295219301418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":46,"alternative-id":["S0006295219301418"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.006","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design and in vivo anti-arthritic activity evaluation of a potent dipeptidyl cyclopropyl nitrile inhibitor of cathepsin C","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2019.04.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}